XML 20 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Sale of Freeline Therapeutics GmbH
6 Months Ended
Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Sale of Freeline Therapeutics GmbH
3.
Sale of Freeline Therapeutics GmbH

On February 8, 2023, the Company sold its German subsidiary, Freeline Therapeutics GmbH, and certain intellectual property rights to Ascend Gene & Cell Therapies Limited ("Ascend") pursuant to a definitive agreement entered into in November 2022 for an aggregate cash purchase price of $25.0 million, subject to purchase price adjustments, and a license back of certain intellectual property rights assigned to Ascend (the "Subsidiary Sale"). The Subsidiary Sale did not meet the criteria for reporting discontinued operations as there was not a strategic shift that has had, or will have, a major effect on the Company's operations. The Company recognized a gain on the Subsidiary Sale of $20.3 million in its unaudited condensed consolidated statement of operations during the six months ended June 30, 2023. Upon the closing of the Subsidiary Sale, the cumulative foreign currency translation losses totaling $0.2 million were released to earnings and included in the gain on the Subsidiary Sale.

In connection with the Subsidiary Sale, the Company and Ascend also entered into a transition services agreement (the "Transition Services Agreement"), pursuant to which Ascend will provide certain services in the area of development and manufacturing to the Company. As part of the Transition Services Agreement, the Company agreed to utilize no fewer than 15 full-time employee equivalents ("FTEs") per annum for a guaranteed period of 18 months following the Transition Services Agreement’s effective date of February 8, 2023. The Company also agreed to pay Ascend a guaranteed minimum of approximately $7.9 million in respect of FTE costs during such period, $2.6 million of which was paid in the three months ended March 31, 2023 and recorded as prepaid expenses. As of June 30, 2023, $0.8 million remained within prepaid and other current assets on the unaudited condensed consolidated balance sheet. The Company will make minimum guaranteed payments to Ascend of $4.8 million and $3.1 million for the years ending December 31, 2023 and 2024, respectively. The Transition Services Agreement will terminate three years after its effective date, unless earlier terminated by Freeline with 90 days' written notice, effective from the end of the 18-month guarantee period at the earliest, in accordance with its terms.

Concurrently with the closing of the Subsidiary Sale, the Company and Ascend entered into an intellectual property deed of assignment and license (the "IP Agreement"), pursuant to which the Company assigned certain intellectual property rights pertaining to the business of Freeline Therapeutics GmbH to Ascend, including certain patents and know-how related to chemistry, manufacturing and controls capabilities and technologies. Ascend granted a non-exclusive, royalty-free, perpetual, irrevocable, worldwide license back to the Company of the assigned rights necessary to develop or commercialize its then-current product candidates. There was no value assigned or recorded for the license back to the Company as the license is considered in-process research and development and had no alternative future use.

The table below sets forth the book value of the Freeline Therapeutics GmbH assets and liabilities sold along with the calculation of the gain on sale based on the cash consideration received.

 

 

 

(in thousands)

 

Book value of assets sold

 

 

 

Cash and cash equivalents

 

$

1,015

 

Prepaid expenses and other current assets

 

 

414

 

Property and equipment, net

 

 

5,470

 

Operating lease right of use assets

 

 

8,455

 

Other non-current assets

 

 

3

 

Amounts attributable to assets sold

 

 

15,357

 

Book value of liabilities sold

 

 

 

Accounts payable

 

 

230

 

Accrued expenses and other current liabilities

 

 

1,430

 

Operating lease liabilities, current

 

 

869

 

Operating lease liabilities, non-current

 

 

8,044

 

Amounts attributable to liabilities sold

 

 

10,573

 

Total identifiable net assets sold

 

 

4,784

 

Less: accumulated other comprehensive loss

 

 

(155

)

Consideration, inclusive of cash transferred

 

 

25,218

 

Gain on sale of Freeline Therapeutics GmbH

 

$

20,279